ISU Abxis Co., Ltd. (KOSDAQ: 086890)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,980.00
-120.00 (-1.97%)
Sep 11, 2024, 2:59 PM KST
-24.87%
Market Cap 218.01B
Revenue (ttm) 62.05B
Net Income (ttm) -5.97B
Shares Out 35.86M
EPS (ttm) n/a
PE Ratio n/a
Forward PE 21.74
Dividend n/a
Ex-Dividend Date n/a
Volume 101,940
Open 6,150.00
Previous Close 6,100.00
Day's Range 5,980.00 - 6,190.00
52-Week Range 5,250.00 - 8,160.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2024

About ISU Abxis

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary inte... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2001
Employees 95
Stock Exchange KOSDAQ
Ticker Symbol 086890
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.